SPRO — Spero Therapeutics Share News
0.000.00%
Last trade - 00:00- $64.64m
- $13.87m
- $66.80m
Spero Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
Brief: Spero Therapeutics Inc Files For Mixed Shelf Offering Of Up To $300 Million - SEC Filing
Spero Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Spero Therapeutics Q4 EPS USD 0.97
Spero Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
Brief: Spero Therapeutics Provides Corporate Update And 2024 Outlook
Brief: Spero Therapeutics Announces First Patient, First Visit For Phase 3 Trial Evaluating Tebipenem HBR
Brief: Spero Therapeutics Appoints Esther Rajavelu As Chief Financial Officer And Chief Business Officer
Spero Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Spero Therapeutics, Inc. Q2 EPS USD -0.23
Spero Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Spero Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Spero Therapeutics Announces Special Protocol Assessment With FDA For Phase 3 Pivot-Po Trial Of Tebipenem HBR
Spero Therapeutics names finance head as CEO; shares down
Brief: Spero Therapeutics Appoints Sath Shukla As President, CEO
Brief: Spero Therapeutics Announces First Quarter 2023 Operating Results And Provides A Business Update
Spero Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview